About this trial
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy with poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment. Immune reconstitution (IR) is critical for improving HSCT efficacy and quality of life among survivors, yet its dynamic impact on survival and complications like chronic graft-versus-host disease (cGVHD) in CMML is poorly defined. This study aimed to investigate the dynamics of IR following HSCT in patients with CMML and evaluate its impact on post-transplant clinical outcomes.
Eligibility criteria
Qualifiers
Patients with confirmed diagnosis of CMML following HSCT
Patients treated at Peking University People's Hospital since January 1, 2005
Disqualifiers
Any condition that may render follow-up data unreliable, including but not limited to severe psychiatric disorders
Patients deemed ineligible for the study by investigators
Trial design
Treatments tested in this trial
- immune reconstitution
Treatment groups
Locations
Sponsors and collaborators
Peking University People's Hospital
Lead sponsor
The First Hospital of Jilin University
Collaborator
960th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Collaborator
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Collaborator